Developer docs
API playgroundTry for free, no card

Search company profiles

Vector Pharma FZCO

Full company profile

uuid005ju4v

Namestring
Vector Pharma FZCO
Legal namestring
Vector Pharma FZCO
Websiteurl
vectorpharma.me
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Vector Pharma FZCO is a Dubai-based pharmaceutical distribution and commercialization company founded in 2019, specializing in rare diseases, oncology, and highly specialized therapeutics. The company serves as a regional gateway for international pharmaceutical innovators seeking to access the Middle East, North Africa, and Turkey (MENAT) markets, where it provides regulatory navigation, market entry, and named-patient program services. It is a founding member of the World Orphan Drug Alliance (WODA), which extends its commercial reach to 158 countries, and holds TRACE International certification alongside GDP and GDPR compliance.

The company's core operations revolve around acting as an exclusive or semi-exclusive commercialization partner for niche pharma manufacturers. Its product portfolio includes oncology assets such as Oncopeptides' Pepaxti (melflufen) and Syndax therapies, as well as rare disease treatments including Theratechnologies' EGRIFTA SV (tesamorelin) and Amryt Pharma's specialty products. Vector Pharma deploys a field force of Key Account Managers and Medical Science Liaisons to engage healthcare professionals, while partnering with EVERSANA and Cencora to extend its distribution and commercialization services infrastructure.

The business model is B2B, generating revenue through distribution margins on high-cost specialty pharmaceuticals and service fees for named-patient programs, regulatory submissions, and market access support. Customers are primarily pharmaceutical innovators — including Oncopeptides, Theratechnologies, Amryt Pharma, Chiesi, Syndax, and Cencora — rather than end patients. The company operates from Al Barsha, Dubai, with a lean team of approximately 16 employees, positioning itself as a focused regional specialist rather than a generalist distributor.

Short descriptiontext

Vector Pharma FZCO is a Dubai-based pharmaceutical distributor and commercialization partner specializing in rare disease, oncology, and specialty therapeutics across the MENA and Turkey region, serving international pharma innovators through regional market access and named-patient programs.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersDubai, United Arab Emirates
HQ citystring
Dubai
HQ countrystring
United Arab Emirates
HQ regionstring
Middle East
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical distribution services, rare disease therapeutics, orphan drug commercialization, specialty pharmaceutical distribution, MENA pharmaceutical services
Industry1 code
PRIMARYCRAOAHAA
Prescription Pharmaceutical (Rx) Wholesale Distribution
NAICS code1 code
  • Drugs and Druggists' Sundries Merchant Wholesalers424210
SIC code1 code
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Specialty Pharmaceutical Distribution
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Product Distribution
TypeTransaction Fee
Description

Vector Pharma distributes pharmaceutical products for rare diseases and oncology in the MENA and Turkey region. Revenue is generated through revenue sharing arrangements with partner companies, such as the agreement with Oncopeptides where revenue is split on all Pepaxti sales in the region, with Vector carrying all costs through their existing structure.

vectorpharma.me
2Named Patient Program Services
TypeTransaction Fee
Description

Sales made on a named patient basis, where doctors request supply of products directly from the manufacturer. This is a key distribution channel for access to treatments not yet fully registered in all markets.

vectorpharma.me
3Commercial Services Partnership
TypeProfessional Services
Description

Strategic partnership with EVERSANA providing commercialization services including consulting, market access, medical communication, pharmacovigilance, and distribution services to pharmaceutical companies expanding into Middle East and North African markets.

vectorpharma.me
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Marketing or Sales, Supply Chain, Technology or R&D, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Vector Pharma FZCO is a full-service pharmaceutical distribution and commercialization partner that distributes rare disease, oncology, and highly specialized therapeutics across the Middle East, North Africa, and Turkey (MENAT) region. The company operates as a founding member of the World Orphan Drug Alliance (WODA), providing integrated services spanning medical affairs, marketing and sales, market access, regulatory affairs, pharmacovigilance, logistics, and independent compliance for biotech and pharmaceutical manufacturers.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Vector Pharma FZCO is a full-service pharmaceutical distribution company specializing in rare diseases, oncology, and highly specialized therapeutics across the MENA and Turkey region. The company operates as a unified platform combining distribution of branded pharmaceutical products (Pepaxti, EGRIFTA SV) with a comprehensive suite of integrated service modules including Medical Affairs, Marketing & Sales, Market Access, Pharmacovigilance/QA Support, Regulatory Affairs, Logistics and Tendering, and Independent Compliance. Vector Pharma serves as a founding member of the World Orphan Drug Alliance (WODA), enabling access to treatments across 158 countries through alliance partnerships. The company's go-to-market approach includes named patient programs for unlicensed medicines alongside full commercialization services.

Product and service9 records
1Pepaxti (melphalan flufenamide) Distribution
CategoryOncology Pharmaceutical Distribution
Description

Distribution of Pepaxti (melphalan flufenamide) for treatment of adults with multiple myeloma who have received at least three prior lines of therapy, used in combination with dexamethasone. Made available to patients across MENA on a named patient basis through partnership with Oncopeptides.

2EGRIFTA SV Distribution
CategoryRare Disease Pharmaceutical Distribution
Description

Distribution of EGRIFTA SV for adults living with HIV who have lipodystrophy and excess abdominal fat, distributed under WODA's Named Patient Program across 41 countries including MENAT markets.

3Medical Affairs Services
CategoryCommercialization Services
Description

Standalone service module providing scientific communication, clinical support, KOL engagement, education and training, market access support, patient advocacy, and real-world evidence collection for orphan and specialty medicines in MENAT.

4Marketing & Sales Services
CategoryCommercialization Services
Description

Standalone service module providing market understanding, targeted messaging, healthcare provider engagement, KOL collaboration, patient-centric approaches, and multi-channel marketing for rare disease and specialty pharmaceutical products in MENAT.

5Market Access Services
CategoryCommercialization Services
Description

Standalone service module providing reimbursement strategy development, Health Technology Assessments, pricing strategy, stakeholder engagement, real-world evidence generation, patient access programs, and policy advocacy for orphan medicines in MENAT.

6Regulatory Affairs Services
CategoryCommercialization Services
Description

Standalone service module providing documentation submission for product registration, regulatory compliance, labeling and packaging compliance, regulatory change monitoring, communication with regulatory authorities, clinical trial oversight, and post-market surveillance across MENAT markets.

7Pharmacovigilance/QA Support Services
CategoryCommercialization Services
Description

Standalone service module providing adverse event monitoring, safety profile evaluation, regulatory reporting, safety communication, database management, quality management systems, GDP compliance, audits and inspections, and deviation management.

8Logistics and Tendering Services
CategoryCommercialization Services
Description

Standalone service module providing supply chain management, inventory management, distribution planning, warehouse operations, transport coordination, tracking and reporting, tender management, market analysis, proposal development, and contract negotiation.

9Independent Compliance Services
CategoryCommercialization Services
Description

Standalone service module providing regulatory adherence, quality assurance, training and education, monitoring and auditing, risk management, reporting and documentation, ethical standards, incident management, and adaptation to regulatory changes.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-03-27
Description

Exclusive collaboration to commercialize Pepaxti (melphalan flufenamide) for the treatment of multiple myeloma in MENA countries including Saudi Arabia, Qatar, UAE, Bahrain, Kuwait, Oman, Algeria, Tunisia, Morocco, Libya, Lebanon, and Iraq. Revenue is split on all Pepaxti sales, with Vector carrying all costs through their existing regional structure.

Strategic tierMajorTypeChannel Partner/ Reseller/ DistributorAnnounced on2023-01-05
Description

Long-term multi-territorial distribution agreement for EGRIFTA SV in 41 countries through WODA. Under the agreement, adults living with HIV who have lipodystrophy and excess abdominal fat can access EGRIFTA SV in markets where it was previously not available. Vector Pharma covers MENAT markets as part of this agreement.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-04-28
Description

Strategic partnership to expand commercial services across Middle East and North African markets. EVERSANA and Vector Pharma now offer ready-to-deploy commercial services including consulting, market access, medical communication, pharmacovigilance, and distribution. This partnership aligns with EVERSANA's continued global growth in the European Union and United Kingdom.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Vector Pharma is a founding member of the World Orphan Drug Alliance (WODA), a global alliance of commercial distributors providing access to treatments for rare diseases and specialty medicines in complex and underserved markets. WODA covers 158 countries across 6 continents through member organizations including Vector Pharma (MENAT), Medis (CEE), Orpharm (Russia/CIS), Orphan DC (LATAM), and others.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Pharmaceutical partner with therapies in rare diseases, hematology, and other highly specialized therapeutics. Partnership established in 2021.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Pharmaceutical partner with rare disease and specialty therapeutics portfolio. Partnership established in 2024.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Biotechnology partner with oncology portfolio. Partnership established in 2025.

Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

Next-generation commercial services partner to the global life sciences industry. Strategic partnership announced in 2022 to expand services across MENAT markets, providing consulting, market access, medical communication, pharmacovigilance, and distribution services.

Strategic tierMinorTypeOthers
Description

Pharmaceutical sourcing and distribution partner. Partnership established in 2025.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeOthers
Description

Swedish biotech developing Pepaxti (melphalan flufenamide) for multiple myeloma. A Vector Pharma distribution partner in 12 MENA markets; representative of the innovative rare-disease/oncology biotechs whose MENA commercialization needs Vector is built to serve.

TypeOthers
Description

Canadian specialty biopharma focused on rare-disease therapeutics including EGRIFTA SV (HIV lipodystrophy). A Vector Pharma distribution partner via WODA, and representative of the biotech client base that Vector serves — comparable as a counterparty profile if not as a direct competitor.

TypeDirect peer
Description

Latin American specialty orphan-drug distributor and WODA founding member. Operates the same regional rare-disease distribution-plus-services model as Vector Pharma and is directly comparable as a peer WODA regional node.

TypeBroad incumbent
Description

Large US-headquartered commercial services platform for life sciences companies covering market access, medical communications, pharmacovigilance and distribution. Vector Pharma's strategic partner but also an overlapping commercial-services provider that competes for similar biotech mandates globally.

TypeDirect peer
Description

Central and Eastern European specialty pharma distributor and fellow WODA founding member covering orphan and rare-disease medicines. Operates the same named-patient-program-to-full-commercialization model as Vector Pharma in its respective region, making it the closest structural twin.

TypeDirect peer
Description

Specialty pharmaceutical company providing access to medicines not commercially available through managed access programs and comparator sourcing. Comparable to Vector Pharma in serving named-patient / managed-access demand for unlicensed rare-disease therapeutics.

TypeDirect peer
Description

Global specialty pharmaceuticals and services company focused on access to unlicensed/unapproved medicines via managed access (named patient) programs and rare-disease commercialization. Highly comparable business model to Vector Pharma's named-patient-plus-distribution offering, though at much larger scale.

TypeBroad incumbent
Description

One of the world's largest pharmaceutical wholesale distributors. Listed as a Vector Pharma partner for distribution services, Cencora operates at a fundamentally different scale but competes for the same specialty/orphan distribution mandates from global pharma manufacturers.

9McKesson
TypeBroad incumbent
Description

Global pharmaceutical distribution and healthcare services giant. Operates specialty distribution arms that compete with regional rare-disease distributors like Vector Pharma for biotech and pharma manufacturer distribution contracts.

10Orpharm
TypeDirect peer
Description

Russia and CIS-focused orphan-drug distributor and WODA founding member. Mirrors Vector Pharma's regional distribution-plus-commercialization model for rare-disease therapeutics, with comparable named-patient and full commercialization capabilities.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Vector Pharma FZCO

Specialty Pharmaceutical Distributionvectorpharma.me

Vector Pharma FZCO is a Dubai-based pharmaceutical distributor and commercialization partner specializing in rare disease, oncology, and specialty therapeutics across the MENA and Turkey region, serving international pharma innovators through regional market access and named-patient programs.

What Vector Pharma FZCO does

Vector Pharma FZCO is a Dubai-based pharmaceutical distribution and commercialization company founded in 2019, specializing in rare diseases, oncology, and highly specialized therapeutics. The company serves as a regional gateway for international pharmaceutical innovators seeking to access the Middle East, North Africa, and Turkey (MENAT) markets, where it provides regulatory navigation, market entry, and named-patient program services. It is a founding member of the World Orphan Drug Alliance (WODA), which extends its commercial reach to 158 countries, and holds TRACE International certification alongside GDP and GDPR compliance.

The company's core operations revolve around acting as an exclusive or semi-exclusive commercialization partner for niche pharma manufacturers. Its product portfolio includes oncology assets such as Oncopeptides' Pepaxti (melflufen) and Syndax therapies, as well as rare disease treatments including Theratechnologies' EGRIFTA SV (tesamorelin) and Amryt Pharma's specialty products. Vector Pharma deploys a field force of Key Account Managers and Medical Science Liaisons to engage healthcare professionals, while partnering with EVERSANA and Cencora to extend its distribution and commercialization services infrastructure.

The business model is B2B, generating revenue through distribution margins on high-cost specialty pharmaceuticals and service fees for named-patient programs, regulatory submissions, and market access support. Customers are primarily pharmaceutical innovators — including Oncopeptides, Theratechnologies, Amryt Pharma, Chiesi, Syndax, and Cencora — rather than end patients. The company operates from Al Barsha, Dubai, with a lean team of approximately 16 employees, positioning itself as a focused regional specialist rather than a generalist distributor.

Vector Pharma FZCO firmographics

Firmographics
Name
Vector Pharma FZCO
Legal name
Vector Pharma FZCO
Website
https://vectorpharma.me
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Short description
Vector Pharma FZCO is a Dubai-based pharmaceutical distributor and commercialization partner specializing in rare disease, oncology, and specialty therapeutics across the MENA and Turkey region, serving international pharma innovators through regional market access and named-patient programs.
Ownership category
akta.pro rank

Vector Pharma FZCO industry classification

Industry
Product category
Specialty Pharmaceutical Distribution
NAICS
Drugs and Druggists' Sundries Merchant Wholesalers (424210)
SIC
Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYCRAOAHAA
Prescription Pharmaceutical (Rx) Wholesale Distribution

Keywords

  • Pharmaceutical distribution services
  • Rare disease therapeutics
  • Orphan drug commercialization
  • Specialty pharmaceutical distribution
  • MENA pharmaceutical services

Where Vector Pharma FZCO is headquartered

Location

Headquarters

HQ city
Dubai
HQ country
United Arab Emirates
HQ region
Middle East

Offices2 records

Markets served

Vector Pharma FZCO business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Supply Chain, Technology or R&D, Others

Revenue model

  1. Product Distribution: Vector Pharma distributes pharmaceutical products for rare diseases and oncology in the MENA and Turkey region. Revenue is generated through revenue sharing arrangements with partner companies, such as the agreement with Oncopeptides where revenue is split on all Pepaxti sales in the region, with Vector carrying all costs through their existing structure.
  2. Named Patient Program Services: Sales made on a named patient basis, where doctors request supply of products directly from the manufacturer. This is a key distribution channel for access to treatments not yet fully registered in all markets.
  3. Commercial Services Partnership: Strategic partnership with EVERSANA providing commercialization services including consulting, market access, medical communication, pharmacovigilance, and distribution services to pharmaceutical companies expanding into Middle East and North African markets.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Vector Pharma FZCO product offering

Product offering

Core offering

Vector Pharma FZCO is a full-service pharmaceutical distribution and commercialization partner that distributes rare disease, oncology, and highly specialized therapeutics across the Middle East, North Africa, and Turkey (MENAT) region. The company operates as a founding member of the World Orphan Drug Alliance (WODA), providing integrated services spanning medical affairs, marketing and sales, market access, regulatory affairs, pharmacovigilance, logistics, and independent compliance for biotech and pharmaceutical manufacturers.

Product overview

Vector Pharma FZCO is a full-service pharmaceutical distribution company specializing in rare diseases, oncology, and highly specialized therapeutics across the MENA and Turkey region. The company operates as a unified platform combining distribution of branded pharmaceutical products (Pepaxti, EGRIFTA SV) with a comprehensive suite of integrated service modules including Medical Affairs, Marketing & Sales, Market Access, Pharmacovigilance/QA Support, Regulatory Affairs, Logistics and Tendering, and Independent Compliance. Vector Pharma serves as a founding member of the World Orphan Drug Alliance (WODA), enabling access to treatments across 158 countries through alliance partnerships. The company's go-to-market approach includes named patient programs for unlicensed medicines alongside full commercialization services.

Differentiator

Problem solved

Functional benefit

Products and services

  • Pepaxti (melphalan flufenamide) Distribution Distribution of Pepaxti (melphalan flufenamide) for treatment of adults with multiple myeloma who have received at least three prior lines of therapy, used in combination with dexamethasone. Made available to patients across MENA on a named patient basis through partnership with Oncopeptides.
  • EGRIFTA SV Distribution Distribution of EGRIFTA SV for adults living with HIV who have lipodystrophy and excess abdominal fat, distributed under WODA's Named Patient Program across 41 countries including MENAT markets.
  • Medical Affairs Services Standalone service module providing scientific communication, clinical support, KOL engagement, education and training, market access support, patient advocacy, and real-world evidence collection for orphan and specialty medicines in MENAT.
  • Marketing & Sales Services Standalone service module providing market understanding, targeted messaging, healthcare provider engagement, KOL collaboration, patient-centric approaches, and multi-channel marketing for rare disease and specialty pharmaceutical products in MENAT.
  • Market Access Services Standalone service module providing reimbursement strategy development, Health Technology Assessments, pricing strategy, stakeholder engagement, real-world evidence generation, patient access programs, and policy advocacy for orphan medicines in MENAT.
  • Regulatory Affairs Services Standalone service module providing documentation submission for product registration, regulatory compliance, labeling and packaging compliance, regulatory change monitoring, communication with regulatory authorities, clinical trial oversight, and post-market surveillance across MENAT markets.
  • Pharmacovigilance/QA Support Services Standalone service module providing adverse event monitoring, safety profile evaluation, regulatory reporting, safety communication, database management, quality management systems, GDP compliance, audits and inspections, and deviation management.
  • Logistics and Tendering Services Standalone service module providing supply chain management, inventory management, distribution planning, warehouse operations, transport coordination, tracking and reporting, tender management, market analysis, proposal development, and contract negotiation.
  • Independent Compliance Services Standalone service module providing regulatory adherence, quality assurance, training and education, monitoring and auditing, risk management, reporting and documentation, ethical standards, incident management, and adaptation to regulatory changes.

Companies that use Vector Pharma FZCO

Customer profile

Named customers1 record

Segments4 records

Ideal customer profiles1 record

Vector Pharma FZCO technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Vector Pharma FZCO partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered core, major and minor.

  • Oncopeptides ABcoreChannel Partner/ Reseller/ Distributor · 27 March 2024Exclusive collaboration to commercialize Pepaxti (melphalan flufenamide) for the treatment of multiple myeloma in MENA countries including Saudi Arabia, Qatar, UAE, Bahrain, Kuwait, Oman, Algeria, Tunisia, Morocco, Libya, Lebanon, and Iraq. Revenue is split on all Pepaxti sales, with Vector carrying all costs through their existing regional structure.
  • Theratechnologies Inc.majorChannel Partner/ Reseller/ Distributor · 5 January 2023Long-term multi-territorial distribution agreement for EGRIFTA SV in 41 countries through WODA. Under the agreement, adults living with HIV who have lipodystrophy and excess abdominal fat can access EGRIFTA SV in markets where it was previously not available. Vector Pharma covers MENAT markets as part of this agreement.
  • EVERSANAcoreStrategic or Co-development Partner · 28 April 2022Strategic partnership to expand commercial services across Middle East and North African markets. EVERSANA and Vector Pharma now offer ready-to-deploy commercial services including consulting, market access, medical communication, pharmacovigilance, and distribution. This partnership aligns with EVERSANA's continued global growth in the European Union and United Kingdom.
  • World Orphan Drug Alliance (WODA)coreStrategic or Co-development PartnerVector Pharma is a founding member of the World Orphan Drug Alliance (WODA), a global alliance of commercial distributors providing access to treatments for rare diseases and specialty medicines in complex and underserved markets. WODA covers 158 countries across 6 continents through member organizations including Vector Pharma (MENAT), Medis (CEE), Orpharm (Russia/CIS), Orphan DC (LATAM), and others.
  • Amryt PharmaminorChannel Partner/ Reseller/ DistributorPharmaceutical partner with therapies in rare diseases, hematology, and other highly specialized therapeutics. Partnership established in 2021.
  • ChiesiminorChannel Partner/ Reseller/ DistributorPharmaceutical partner with rare disease and specialty therapeutics portfolio. Partnership established in 2024.
  • Syndax PharmaceuticalsminorChannel Partner/ Reseller/ DistributorBiotechnology partner with oncology portfolio. Partnership established in 2025.
  • Eversana (commercial services)coreImplementation/ SI/ Consulting PartnerNext-generation commercial services partner to the global life sciences industry. Strategic partnership announced in 2022 to expand services across MENAT markets, providing consulting, market access, medical communication, pharmacovigilance, and distribution services.
  • CencoraminorOthersPharmaceutical sourcing and distribution partner. Partnership established in 2025.

Scale indicators6 records

Recent moves8 records

Expansion highlights5 records

Vector Pharma FZCO competitors and assessment

Company assessment

Others

  • Oncopeptides AB: Swedish biotech developing Pepaxti (melphalan flufenamide) for multiple myeloma. A Vector Pharma distribution partner in 12 MENA markets; representative of the innovative rare-disease/oncology biotechs whose MENA commercialization needs Vector is built to serve.
  • Theratechnologies: Canadian specialty biopharma focused on rare-disease therapeutics including EGRIFTA SV (HIV lipodystrophy). A Vector Pharma distribution partner via WODA, and representative of the biotech client base that Vector serves — comparable as a counterparty profile if not as a direct competitor.

Direct peers

  • OrphanDC: Latin American specialty orphan-drug distributor and WODA founding member. Operates the same regional rare-disease distribution-plus-services model as Vector Pharma and is directly comparable as a peer WODA regional node.
  • Medis: Central and Eastern European specialty pharma distributor and fellow WODA founding member covering orphan and rare-disease medicines. Operates the same named-patient-program-to-full-commercialization model as Vector Pharma in its respective region, making it the closest structural twin.
  • Inceptua Group: Specialty pharmaceutical company providing access to medicines not commercially available through managed access programs and comparator sourcing. Comparable to Vector Pharma in serving named-patient / managed-access demand for unlicensed rare-disease therapeutics.
  • Clinigen Group: Global specialty pharmaceuticals and services company focused on access to unlicensed/unapproved medicines via managed access (named patient) programs and rare-disease commercialization. Highly comparable business model to Vector Pharma's named-patient-plus-distribution offering, though at much larger scale.
  • Orpharm: Russia and CIS-focused orphan-drug distributor and WODA founding member. Mirrors Vector Pharma's regional distribution-plus-commercialization model for rare-disease therapeutics, with comparable named-patient and full commercialization capabilities.

Broad incumbents

  • EVERSANA: Large US-headquartered commercial services platform for life sciences companies covering market access, medical communications, pharmacovigilance and distribution. Vector Pharma's strategic partner but also an overlapping commercial-services provider that competes for similar biotech mandates globally.
  • Cencora (formerly AmerisourceBergen): One of the world's largest pharmaceutical wholesale distributors. Listed as a Vector Pharma partner for distribution services, Cencora operates at a fundamentally different scale but competes for the same specialty/orphan distribution mandates from global pharma manufacturers.
  • McKesson: Global pharmaceutical distribution and healthcare services giant. Operates specialty distribution arms that compete with regional rare-disease distributors like Vector Pharma for biotech and pharma manufacturer distribution contracts.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Vector Pharma FZCO social profiles

Digital presence

Vector Pharma FZCO compliance and trust

Trust signal

Compliance3 records

Vector Pharma FZCO financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Vector Pharma FZCO leadership team

Management profile

Number of profiles

Profiles3 records

Vector Pharma FZCO funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Vector Pharma FZCO M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vector Pharma FZCO

What does Vector Pharma FZCO do?

Vector Pharma FZCO is a full-service pharmaceutical distribution and commercialization partner that distributes rare disease, oncology, and highly specialized therapeutics across the Middle East, North Africa, and Turkey (MENAT) region. The company operates as a founding member of the World Orphan Drug Alliance (WODA), providing integrated services spanning medical affairs, marketing and sales, market access, regulatory affairs, pharmacovigilance, logistics, and independent compliance for biotech and pharmaceutical manufacturers.

Is Vector Pharma FZCO a public or private company?

Vector Pharma FZCO is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Vector Pharma FZCO founded?

Vector Pharma FZCO was founded in 2019. It employs 11 to 50 people.

Where is Vector Pharma FZCO based?

Vector Pharma FZCO is headquartered in Dubai, United Arab Emirates, in the Middle East region.

How does Vector Pharma FZCO make money?

Three revenue lines are on record. Product Distribution is the primary driver. The others are named Patient Program Services and commercial Services Partnership.

Who are Vector Pharma FZCO's main competitors?

Others on record are Oncopeptides AB and Theratechnologies. Direct peers are OrphanDC, Medis, Inceptua Group, Clinigen Group and Orpharm. Broad incumbents are EVERSANA, Cencora (formerly AmerisourceBergen) and McKesson.

Does Vector Pharma FZCO have an API?

No public API is recorded for Vector Pharma FZCO.

What industry is Vector Pharma FZCO in?

Vector Pharma FZCO's product category is Specialty Pharmaceutical Distribution. Its primary akta.pro industry code is CRAOAHAA, Prescription Pharmaceutical (Rx) Wholesale Distribution. Its NAICS code is 424210 and its SIC code is 5122.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireOncopeptides and Vector Pharma FZCO Announce Collaboration to Provide Pepaxti to Patients in the Middle East and North AfricaOncopeptides and Vector Pharma FZCO announced an exclusive collaboration to distribute Pepaxti for multiple myeloma in MENA countries. Vector will carry all costs and sales are on a named patient basis. The partnership may unlock additional geographies under discussion.GlobeNewswireVector Pharma FZCO Announce Exclusive Distribution Agreement with Ascendis Pharma A/S for Skytrofa (lonapegsomatropin) and Yorvipath (palopegteriparatide) in Gulf Cooperation Council CountriesVector Pharma FZCO announced an exclusive distribution agreement with Ascendis Pharma to commercialize Skytrofa and Yorvipath in GCC countries. The drugs treat pediatric growth hormone deficiency and adult hypoparathyroidism, respectively. The agreement aims to bring TransCon technology-based therapeutics to the region.YahooVector Pharma FZCO Announce Exclusive Distribution Agreement with Ascendis Pharma A/S for Skytrofa (lonapegsomatropin) and Yorvipath (palopegteriparatide) in Gulf Cooperation Council CountriesVector Pharma FZCO announced an exclusive distribution agreement with Ascendis Pharma to commercialize Skytrofa and Yorvipath in GCC countries. The drugs treat pediatric growth hormone deficiency and adult hypoparathyroidism, respectively. The agreement aims to bring TransCon technology-based therapeutics to the region.GlobeNewswireRenalytix Announces Middle East Distribution Agreement with Vector PharmaRenalytix announced a distribution agreement with Vector Pharma to expand kidneyintelX.dkd testing in Saudi Arabia, Bahrain, Qatar, Oman, Kuwait, and the UAE. The agreement targets an estimated 4 million diabetic kidney disease patients in the region, which has high diabetes prevalence. Vector Pharma will focus on building awareness and driving adoption to meet annual sales targets.PR NewswireEVERSANA™ and Vector Pharma FZCO Announce Strategic Partnership to Expand Commercialisation Services Throughout Middle East and North AfricaEVERSANA and Vector Pharma FZCO announced a strategic partnership to expand commercial services across the Middle East and North Africa. The partnership offers consulting, market access, medical communication, pharmacovigilance, and distribution, with additional services in progress. It aligns with EVERSANA's global growth and Vector's regional expertise.PR NewswireEVERSANA™ and Vector Pharma FZCO Announce Strategic Partnership to Expand Commercialisation Services Throughout Middle East and North AfricaEVERSANA and Vector Pharma FZCO announced a strategic partnership to expand commercial services across the Middle East and North Africa. The partnership offers consulting, market access, medical communication, pharmacovigilance, and distribution, with additional services in progress. It aligns with EVERSANA's global growth and Vector's regional expertise.BioSpaceVector Pharma FZCO signs Exclusive License and Distribution Rights to IXEMPRA in the Middle EastVector Pharma FZCO signed an exclusive distribution agreement with R-PHARM US to import and distribute IXEMPRA in the Middle East and North Africa. The drug is indicated for metastatic or locally advanced breast cancer resistant to anthracyclines, taxanes, and capecitabine.GlobeNewswireVector Pharma FZCO signs Exclusive License and Distribution Rights to IXEMPRA in the Middle EastVector Pharma FZCO signed an exclusive distribution agreement with R-PHARM US to import, market, and distribute Ixempra in Middle East and North African territories. The drug is indicated for metastatic or locally advanced breast cancer resistant to anthracyclines, taxanes, and capecitabine.